Skip to main content

Table 1 Baseline Characteristics of Patients with Chronic Kidney Disease (CKD) and Major Depressive Disorder (MDD) Randomized to Sertraline versus Placebo

From: Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial

Variable

CKD+/MDD+

(n = 175)

Sertraline

(n = 88)

Placebo

(n = 87)

P-value

Age, years, mean ± SD

58 ± 13

58 ± 13

58 ± 13

0.95

BMI, kg/m2, mean ± SD

33.4 ± 17.2

31.4 ± 8.8

35.4 ± 22.7

0.13

Women, n (%)

46 (26)

24 (27)

22 (25)

0.77

African American, n (%)

97 (55)

50 (57)

47 (54)

0.78

Diabetes mellitus, n (%)

103 (59)

48 (55)

55 (63)

0.28

Proton pump inhibitor use, n (%)

46 (26)

21 (24)

25 (29)

0.46

Beta blocker use, n (%)

116 (66)

61 (69)

55 (63)

0.39

Statin use, n (%)

109 (62)

53 (60)

56 (64)

0.57

ACEI/ARB use, n (%)

102 (58)

53 (60)

49 (56)

0.60

eGFR, mL/min/1.73 m2, mean ± SD

27 ± 13

28 ± 13

27 ± 13

0.74

Urine albumin-to-creatinine ratio, mg/g, median (IQR)

337 (0.5–10,250)

312 (0.5–7032)

555 (9–7723)

0.19

Hemoglobin, g/dL, mean ± SD

12.4 ± 7.6

13.0 ± 10.4

11.9 ± 2.3

0.36

White blood cell count, K per μL, mean ± SD

7 ± 3

7.0 ± 2.8

7.0 ± 2.7

0.92

Platelet count, K per μL, mean ± SD

224 ± 72

223 ± 81

226 ± 61

0.80

Serum total cholesterol, md/dL, mean ± SD

169 ± 47

168 ± 45

169 ± 49

0.85

Serum triglycerides, mg/dL, mean ± SD

147 ± 88

139 ± 73

155 ± 102

0.25

Serum LDL, mg/dL, median (IQR)

86 (14–284)

89 (32–252)

85 (14–287)

0.88

Serum total bilirubin, mg/dL, mean ± SD

1.0 ± 5.6

1.4 ± 8.0

0.5 ± 0.2

0.28

Hemoglobin A1c, %, mean ± SD

7.0 ± 4.0

6.8 ± 1.7

7.3 ± 5.4

0.34

Serum albumin, g/dL, mean ± SD

3.8 ± 0.6

3.8 ± 0.6

3.8 ± 0.5

0.93

Serum uric acid, mg/dL, mean ± SD

8.3 ± 2.1

8.2 ± 2.4

8.3 ± 1.8

0.83

Serum calcium, mg/dL, mean ± SD

9.1 ± 0.9

9.1 ± 0.8

9.1 ± 1.0

0.62

Serum phosphorus, mg/dL, mean ± SD

4.1 ± 0.9

4.0 ± 0.8

4.2 ± 1.0

0.09

Serum parathyroid hormone, ng/L, median (IQR)

127 (2–1629)

125 (5–708)

137 (20–1629)

0.37

Serum 25-hydroxyvitamin D, pg/L, mean ± SD

28 ± 15

30 ± 16

26 ± 13

0.09

QIDS-SR16 score, median (IQR)

12 (10–21)

12 (3–21)

12 (10–18)

0.15

  1. For Gaussian continuous variables, means ±SD and P-values for the one way ANOVA F-test are reported. For non-Gaussian continuous variables, median (minimum-maximum) and P-values for non-parametric Wilcoxon rank sum test are reported. For categorical variables, P-values for the Pearson Chi-Square test are reported
  2. Abbreviations: ACEI/ARB Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, BMI Body mass index, eGFR Estimated glomerular filtration rate, IQR Interquartile range, LDL Low density lipoprotein, SD Standard deviation, QIDS-SR16–16-item Quick Inventory for Depression Symptomatology Self-Report. MDD+/CKD+ represents participants from the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) Study with major depressive disorder and chronic kidney disease
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us